Telerehabilitation treats arm function after stroke, may increase access
Click Here to Manage Email Alerts
Telerehabilitation therapy was not inferior to in-clinic rehabilitation therapy in improving arm function after stroke, according to study results published in JAMA Neurology.
The findings suggest that telerehabilitation could substantially increase access to therapy for those who are unable to access a rehabilitation clinic, according to study authors.
“Few patients fully recover from arm weakness after a stroke. The remainder demonstrate persistent arm impairments that are directly linked to activity limitations, participation restrictions, reduced quality of life, and decreased well-being,” Steven C. Cramer, MD, of the department of neurology at the University of California, Irvine, and colleagues wrote. “Some rehabilitation therapies can improve these deficits, with higher doses associated with better outcomes.
“However, many patients do not receive high doses of rehabilitation therapy, for reasons that include cost, difficulty traveling to the location where therapy is provided, shortage of regional rehabilitation care, and poor adherence with assignments,” they continued.
Cramer and colleagues conducted a randomized, assessor-blinded, noninferiority clinical trial to compare telerehabilitation and in-clinic rehabilitation therapy outcomes for patients who had a stroke that resulted in arm motor deficit.
Patients were enrolled in the study at 4 to 36 weeks after experiencing an ischemic stroke or intracerebral hemorrhage that resulted in arm weakness. After enrollment, participants were randomly assigned to receive intensive arm motor therapy in a rehabilitation clinic or in their home using telerehabilitation delivery services with a computer connected to the internet. Scores on the Fugl-Myer arm motor scale were measured at the baseline and after treatment to determine changes in arm motor function.
All patients received 36 treatment sessions (70 minutes) in a 6- to 8-week period, which included 18 supervised and 18 unsupervised sessions. The content of therapy was carefully matched, with each group using the same exercises and standard exercise equipment.
A total of 124 participants were included in the study. Participants had a mean age of 61 years, a mean baseline Fugl-Meyer score of 43 points and were enrolled for a mean 18.7 weeks following stroke.
Patients in the in-clinic group were adherent to 33.6 of 36 therapy sessions (93.3%) and those who received telerehabilitation at home were adherent to 35.4 of 36 therapy sessions (98.3%).
Both groups experienced significant changes in Fugl-Meyer scores from the baseline period to 30 days after treatment, with a mean change of 8.36 points in patients who received in-clinic therapy and 7.86 points in those who received telerehabilitation therapy.
The noninferiority margin was 2.47 and fell outside the 95% confidence interval, suggesting that telerehabilitation was not inferior to in-clinic therapy.
“Our study found that a 6-week course of daily home based [telerehabilitation] is safe, is rated favorably by patients, is associated with excellent treatment adherence, and produces substantial gains in arm function that were not inferior to dose matched interventions delivered in the clinic,” Cramer and colleagues wrote. – by Erin Michael
Disclosures: Cramer reported receiving grants from the NIH during the conduct of the study; serving as a consultant for and receiving personal fees from AbbVie, Constant Pharmaceutical, Dart Neuroscience, Microtransponder, Neurolutions, Regenera, Roche, SanBio, Stemedica, Toyama and TRCare outside the submitted work; and having a patent pending to No.15/254,029 “Systems And Methods For Facilitating Rehabilitation Therapy.” Please see study for all other authors’ relevant financial disclosures.